Latest Breaking News On - Akseli hemminki - Page 1 : comparemela.com

TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024

TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesEteläuomen läiAkseli hemminkiAino kalervoDaniel goochMerck co incMerck kgaAmerican society of clinical oncologyUs department of defenseUniversity of helsinkiMerck sharp dohmeHealth affairsMerck kgaaEuropean innovation councilDepartment of defenseScius communications

TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024

Results Reveal Mechanism of Action and Correlative Analyses DataHELSINKI, Finland, April 10, 2024 (GLOBE NEWSWIRE) TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies presented promising preliminary safety and efficacy data from their ongoing Phase I clinical trial (NCT05271318) in platinum resistant or refractory ovarian cancer patients at the American Association for Cancer Research (AACR) Annual Meeting 2024. TILT-123 in combination with MS

Eteläuomen läiUnited statesAkseli hemminkiAino kalervoDaniel goochUs department of defenseMerck kgaaMerck co incMerck sharp dohmeEuropean innovation councilUniversity of helsinkiAmerican association for cancer researchScius communicationsMerck kgaResults reveal mechanismCorrelative analyses

Finland s TILT Biotherapeutics gets $2M grant from US Department of Defense for ovarian cancer immunotherapy research

Finland s TILT Biotherapeutics gets $2M grant from US Department of Defense for ovarian cancer immunotherapy research
arcticstartup.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from arcticstartup.com Daily Mail and Mail on Sunday newspapers.

United statesEteläuomen läiAkseli hemminkiMerck kgaUs department of defenseMerck kgaaUniversity of helsinkiMayo clinic

TILT Biotherapeutics awarded $2 million grant for ovarian cancer research

TILT Biotherapeutics, a clinical-stage biotech company developing cancer immunotherapies, has received a $2 million grant from the U.S. Department of Defense (DOD) for a three-year project to treat ovarian cancer using its TILT-123 asset.

Akseli hemminkiMayo clinicBio developmentsMarkets amp regulationsBiopharma cultureEmerging marketsIlt biotherapeuticsOvarian cancer

TILT Biotherapeutics Awarded USD 2M Grant from US Department of Defense for Ovarian Cancer Immunotherapy Research

TILT Biotherapeutics Awarded USD 2M Grant from US Department of Defense for Ovarian Cancer Immunotherapy Research
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesEteläuomen läiAino kalervoAkseli hemminkiDaniel goochMerck co incOvarian cancer immunotherapy researchEuropean innovation councilUs department of defenseOvarian cancer research program under award noMerck kgaaDepartment of defenseHealth affairsUniversity of helsinkiScius communicationsMerck kga